Peptide Relay

Gathering the record

Loading the next view…

Relay is organizing the evidence and source boundaries.

Compound library

Peptide analog

Selective, long-acting amylin receptor agonist

Eloralintide

Investigational — Phase 3

An experimental weight-loss drug designed to affect fullness and appetite.

6-minute readFull profile reviewed July 30, 2026

Evidence is explained by question. Dosing references show their own check dates.

60-second overview

Eloralintide at a glance

Why people look into it, what studies found, and what is still unknown.

Why people look into it: Weight loss and whether its side effects differ from other appetite-related drugs.
What studies found: A 48-week study found substantial weight loss in adults without diabetes. Nausea and fatigue differed between the study groups.
What is still unclear: Larger studies, long-term safety, and benefits for other conditions still need confirmation. It is not approved.

About the evidence and review date

Educational information only. Evidence reviewed through July 30, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.

Research questions

Why people research it

Each label shows how much evidence supports that question.

Weight lossSupported by human studies
Reduced appetite and feeling fullerSupported by human studies
Long-term weight managementCurrently being studied
Weight management with type 2 diabetesCurrently being studied
Obstructive sleep apneaCurrently being studied
Knee osteoarthritis pain and functionCurrently being studied
Add-on research with weekly incretin therapyCurrently being studied

What studies show

What the evidence supports

The research behind the answer

A 263-participant randomized, double-blind Phase 2 trial reported mean 48-week body-weight reductions ranging from 9% to 20% across studied eloralintide arms versus 0.4% with placebo under the efficacy estimand.

See each finding and its sources (9)

Registered trial — no results

Eloralintide is an investigational selective amylin receptor agonist in Phase 3 development, not an FDA-approved medicine.

The ENLIGHTEN Phase 3 program is recruiting across obesity and related populations. No FDA-approved eloralintide product label, consumer dose, or official handling instructions were identified.

A Phase 3 program indicates development maturity, not regulatory approval or confirmed Phase 3 benefit.

Trial registryStudy phase, intervention, and recruitment status

Mechanistic rationale

Eloralintide was designed to activate human AMY1R more selectively than calcitonin and AMY3 receptors.

In-vitro discovery work reported roughly 12-fold greater potency at human AMY1R than at the calcitonin receptor and roughly 11-fold greater potency than at AMY3R.

Assay selectivity does not prove that one receptor explains clinical weight loss, tolerability, or individual outcomes in people.

Peer reviewedIn-vitro receptor pharmacology

Controlled human study

A 48-week randomized Phase 2 trial found dose-related average body-weight reduction with eloralintide in adults without type 2 diabetes.

Mean change under the efficacy estimand ranged from -9% to -20% across studied eloralintide arms versus -0.4% with placebo.

Individual arms were small, the study excluded type 2 diabetes, and studied trial regimens are not approved dosing guidance or individualized expectations.

Peer reviewedWeek 48 body-weight outcomes

Controlled human study

Early Phase 1 studies established once-weekly pharmacokinetic feasibility and produced short-term weight-loss signals.

The 100-participant multiple-dose study reported a roughly two-week half-life range and mean 12-week weight reductions across cohorts, while an earlier single-dose study supported progression into weekly development.

These were early, short studies designed primarily for safety, tolerability, and pharmacokinetics rather than definitive efficacy.

Peer reviewedSingle-ascending-dose clinical portion

Peer reviewedPharmacokinetic and week-12 results

Controlled human study

Nausea and fatigue were the most common adverse events in the Phase 2 trial, with rates that varied across dose and escalation arms.

Nausea ranged from 11% to 64% across eloralintide arms and fatigue from 0% to 46%, compared with 14% and 12% with placebo, respectively.

One 263-participant trial cannot define rare, long-term, or population-wide safety. Phase 3 safety results remain pending.

Peer reviewedAdverse-event findings

Trial registryPhase 3 safety outcomes; no results posted

Registered trial — no results

The ENLIGHTEN program is testing eloralintide across obesity without diabetes, obesity with type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and persistent obesity during incretin therapy.

These registrations show the breadth of the development program and the outcomes researchers plan to measure.

Active registrations do not demonstrate that eloralintide improves any of these outcomes. Each indication requires its own completed results.

Trial registryStudy overview

Controlled human study

Published and registered eloralintide studies describe once-weekly subcutaneous administration, but they do not provide consumer dosing guidance.

The study records document protocol-specific doses, escalation schemes, eligibility, and sponsor-controlled injections to explain how research was conducted.

Eloralintide has no approved product label. Trial methods should not be converted into self-directed administration or combination instructions.

Peer reviewedMethods

Trial registryArms and interventions

Registered trial — no results

No public, regulator-approved eloralintide reconstitution, storage, or stability instructions were identified.

Official trial records describe sponsor-controlled investigational injections rather than a marketed consumer product or general handling method.

Investigational-product handling cannot validate the identity, sterility, concentration, storage, or stability of material obtained elsewhere.

Trial registryInvestigational intervention record

Mechanistic rationale

Eloralintide should not be treated as interchangeable with cagrilintide, incretin medicines, or combination regimens.

Eloralintide has a distinct receptor-selectivity profile and its current monotherapy evidence comes from its own trials. Add-on and combination programs remain separate evidence records.

Mechanistic differences do not establish clinical superiority, better tolerability, or safe combination use. Direct comparative and combination outcome evidence remains limited or pending.

Trial registryAdd-on Phase 3 design; no results posted

Peer reviewedReceptor selectivity and comparator experiments

Risks & unknowns

What needs caution

Reported side effects

Nausea and fatigue were the most common adverse events in the Phase 2 trial, with rates that varied across dose and escalation arms.

Controlled human evidence

One 263-participant trial cannot define rare, long-term, or population-wide safety. Phase 3 safety results remain pending.

Open source

Missing reports do not establish safety. Findings apply to the product, route, amounts, population, comparison, and follow-up studied.

Side-effect frequency, study withdrawals, and gaps

How often side effects occurred

Nausea and fatigue were the most common adverse events in the Phase 2 trial, with rates that varied across dose and escalation arms.

Controlled human evidence

The stated frequency is source-, product-, population-, route-, dose-, comparator-, and duration-specific; it is not a universal incidence estimate.

Open source

Why people stopped in studies

Relay has not verified which side effects led people to stop treatment in studies.

Evidence boundary

This is an evidence gap, not proof that discontinuations did not occur.

Warning information

Relay has not verified a compound-specific warning summary for this profile.

Evidence boundary

Investigational; Phase 3 ENLIGHTEN program active, with no FDA-approved eloralintide product Whether the large ENLIGHTEN Phase 3 trials confirm long-term efficacy, tolerability, rare-event safety, durability, and benefit in diabetes, sleep apnea, osteoarthritis, and incretin add-on settings.

Emergency instructions

This profile does not contain verified, product-specific emergency instructions.

Evidence boundary

Relay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.

Dosing references

Dosing & preparation

Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.

Route: SubQ · Under the skin

Human study · source-specific regimenWhat this means

Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.

Eloralintide · Phase 2 dose groups

The trial enrolled 263 adults with obesity or overweight without type 2 diabetes.

Amount in this source: 1, 3, 6, or 9 mg groups
Frequency: Once weekly
Treatment period: 48 weeks

Eloralintide · Phase 2 dose groups
Trial pattern	Assigned amounts
Fixed-dose groups	1, 3, 6, or 9 mg
Separate escalation groups	6 → 9 mg or 3 → 9 mg

The abstract identifies these groups but does not give every step's timing. No intermediate schedule is inferred.

Eloralintide · randomized 48-week Phase 2 trial Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.

Preparation & concentration · SubQ

This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.

Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.

Open concentration calculator

Starting dose, maintenance, and trial targets explained

Starting dose: the amount used at the beginning of the named label schedule or trial.

Maintenance: the ongoing amount described by that product label.

Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.

Other source records, populations, and limits · all routes

Direct human study

Eloralintide Phase 2 study material

Amount in this source: See the named dosing references above; this additional source record does not add a verified amount.
Frequency: Once weekly across fixed and escalating research arms
Route: Subcutaneous injection
Duration: 48 weeks

Population, study design, and limitations

A published Phase 2 trial investigated eloralintide in adults with obesity or overweight plus a related condition who did not have type 2 diabetes.

Population: Adults with obesity, or overweight plus at least one weight-related comorbidity, without type 2 diabetes

Design: Multicenter, double-blind, randomized, placebo-controlled parallel-group trial

The trial included several distinct study arms; they do not form one transferable sequence.
Phase 2 results do not establish Phase 3 benefit, approval, or preparation rules for independently sourced material.

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trialSelected study record

Mechanisms

How it works

Eloralintide (LY3841136) is a lipidated, long-acting amylin analogue designed for preferential human AMY1R activation with lower in-vitro potency at AMY3R and the calcitonin receptor. Published human evidence includes a 48-participant single-ascending-dose study, a 100-participant multiple-ascending-dose study, and a 263-participant 48-week randomized Phase 2 obesity trial. Phase 3 studies are evaluating obesity with and without type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and persistent obesity during stable incretin therapy. These registered studies have no posted outcome results at the current cutoff.

Why this matters

A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.

Signals and targets

Proposed biological steps

Selective amylin-receptor agonism
AMY1R-predominant signaling
Satiety and food-intake signaling

Research reference

How mature is the evidence?

A reference for the studies, populations, and routes behind this profile.

Research depthAdvanced human development program

Published Phase 1 and 48-week Phase 2 trials are joined by a broad active Phase 3 program.

Why this matters

Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.

Evidence confidenceModerate for Phase 2 outcomes

The controlled weight signal is substantial, but pivotal replication, rare-event safety, and durability remain pending.

Why this matters

Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.

Strongest evidenceA 263-person randomized 48-week Phase 2 trial

Why this matters

The strongest evidence type shows what the best-supported conclusions are actually based on.

Human evidencePromising controlled weight evidence; Phase 3 confirmation pending

Why this matters

Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.

Route-specific record

Which product or study does this describe?

Eloralintide Phase 2 study materialAmounts and schedules below belong to this source record.Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Administration reference reviewed Aug 5, 2026

Route studiedSubcutaneous injection

Schedules studiedOnce weekly across fixed and escalating research arms; 48 weeks

Amounts studiedWithheld: this record provides research context without a transferable amount

Why this matters

These are exposures used in cited research for a specific route and population—not an instruction for an individual.

Half-lifeNot established for this exact editorial record

Why this matters

Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.

Route evidenceA published Phase 2 trial investigated eloralintide in adults with obesity or overweight plus a related condition who did not have type 2 diabetes.

Why this matters

Evidence can change by administration method. Findings from one route should not automatically be applied to another.

Evidence boundary: The trial included several distinct study arms; they do not form one transferable sequence. Phase 2 results do not establish Phase 3 benefit, approval, or preparation rules for independently sourced material. Amounts shown describe cited research exposure—not a dosage recommendation.

Studies

Study-by-study record

Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.

Why this matters

A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.

Controlled human studyPeer reviewed

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Peer reviewed

PhasePhase 1b

Population100 participants

Duration12 weeks

Design and population

Randomized, placebo-controlled, participant- and investigator-blinded multiple ascending-dose study

Adults with obesity or overweight without diabetes

Outcomes measured

Safety and tolerability
Pharmacokinetics
Appetite and gastric-emptying measures
Percent change in body weight

What was reported

Exposure was approximately dose proportional, and mean body-weight reduction across eloralintide cohorts ranged from 2.6% to 11.3% at week 12. Decreased appetite, headache, and fatigue were among the most common reported events.

Study administration and important limits

Study administration: Once-weekly subcutaneous eloralintide across five dose cohorts without within-participant escalation, or placebo

Limitations: This was a short, early-phase dose-cohort study with small groups and exploratory pharmacodynamic outcomes. It cannot establish long-term efficacy, comparative effectiveness, or rare safety.

Controlled human studyPeer reviewed

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Peer reviewed

PhasePhase 2

Population263 participants

Duration48 weeks

Design and population

Multicenter, double-blind, randomized, placebo-controlled parallel-group trial

Adults with obesity, or overweight plus at least one weight-related comorbidity, without type 2 diabetes

Outcomes measured

Percent change in body weight
Weight-reduction thresholds
Treatment discontinuation
Adverse events

What was reported

At week 48, mean body-weight change under the efficacy estimand ranged from -9% to -20% across eloralintide arms versus -0.4% with placebo. Nausea and fatigue were the most common adverse events, with rates varying substantially by arm.

Study administration and important limits

Study administration: Once-weekly subcutaneous eloralintide across fixed-dose and dose-escalation arms, or placebo

Limitations: This sponsor-funded dose-ranging trial excluded type 2 diabetes and used relatively small individual arms. Its studied doses and escalation schemes are research methods, not approved dosing guidance, and group averages are not individual predictions.

Controlled human studyPeer reviewed

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

Peer reviewed

PhasePhase 1 single ascending dose

Population48 participants

DurationSingle dose with approximately four weeks of body-weight follow-up

Design and population

Randomized, placebo-controlled, participant- and investigator-blinded single-dose study with translational preclinical experiments

Healthy adults in the clinical portion

Outcomes measured

Safety and tolerability
Pharmacokinetics
Body-weight change
In-vitro receptor potency and animal food-intake effects

What was reported

The translational study reported preferential human AMY1R activation over calcitonin and AMY3 receptors in vitro. In the clinical portion, selected higher single-dose cohorts had larger mean week-4 weight reductions than placebo.

Study administration and important limits

Study administration: Single subcutaneous eloralintide doses or placebo

Limitations: The receptor findings came from assays and animal models, while the human study was small, single-dose, and performed in healthy participants. It cannot establish receptor-specific clinical benefit or long-term obesity outcomes.

Registered trial — no resultsTrial registry

ENLIGHTEN-1: A Study of Eloralintide in Participants With Obesity, or Overweight Without Type 2 Diabetes

Trial registry

PhasePhase 3

Population1980 participants

Duration64-week primary phase; participants with prediabetes continue into a longer extension

Design and population

Randomized, double-blind, placebo-controlled parallel study

Adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes

Outcomes measured

Percent change in body weight
Body-fat mass and waist circumference
Cardiometabolic measures
Progression from prediabetes to type 2 diabetes
Safety and tolerability

What was reported

ENLIGHTEN-1 was recruiting with no results posted as of the July 30, 2026 evidence cutoff.

Study administration and important limits

Study administration: Once-weekly subcutaneous eloralintide or placebo

Limitations: The registration describes planned methods and outcomes. It does not establish efficacy, safety, or diabetes prevention.

Registered trial — no resultsTrial registry

ENLIGHTEN-2: A Study of Eloralintide in Participants With Obesity or Overweight, and Type 2 Diabetes

Trial registry

PhasePhase 3

Population1035 participants

Duration64-week primary treatment period; approximately 75 weeks total participation

Design and population

Randomized, double-blind, placebo-controlled parallel study

Adults with obesity or overweight and type 2 diabetes

Outcomes measured

Percent change in body weight
Body-fat mass and waist circumference
HbA1c and fasting metabolic measures
Quality of life
Safety and tolerability

What was reported

ENLIGHTEN-2 was recruiting with no results posted as of the July 30, 2026 evidence cutoff.

Study administration and important limits

Study administration: Once-weekly subcutaneous eloralintide or placebo

Limitations: The registry establishes the study question, not whether eloralintide improves weight, glucose, or safety outcomes in type 2 diabetes.

Registered trial — no resultsTrial registry

ENLIGHTEN-4: Efficacy and Safety of Eloralintide in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Trial registry

PhasePhase 3

Population900 participants

DurationApproximately 75 weeks

Design and population

Two randomized, double-blind, placebo-controlled studies within one knee-osteoarthritis program

Adults with obesity or overweight and symptomatic knee osteoarthritis

Outcomes measured

Knee-pain and physical-function measures
Percent change in body weight
Quality of life
Safety and tolerability

What was reported

ENLIGHTEN-4 was recruiting with no results posted as of the July 30, 2026 evidence cutoff.

Study administration and important limits

Study administration: Once-weekly subcutaneous eloralintide or placebo

Limitations: The registration does not demonstrate pain relief, improved function, or whether any future change would be mediated by weight loss or another pathway.

Registered trial — no resultsTrial registry

ENLIGHTEN-6: A Study of Eloralintide in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Trial registry

PhasePhase 3

Population900 participants

DurationApproximately 80 weeks

Design and population

Randomized, double-blind, placebo-controlled parallel study

Adults with persistent obesity or overweight despite stable weekly incretin background therapy, with or without type 2 diabetes

Outcomes measured

Percent change in body weight
Weight-reduction thresholds
Cardiometabolic measures
Safety and tolerability

What was reported

ENLIGHTEN-6 was recruiting with no results posted as of the July 30, 2026 evidence cutoff.

Study administration and important limits

Study administration: Once-weekly subcutaneous eloralintide or placebo added to stable weekly incretin therapy

Limitations: This add-on study cannot be used to claim benefit, safety, or compatibility before results are available. It also does not provide self-directed combination guidance.

Registered trial — no resultsTrial registry

ENLIGHTEN-3: A Study of Eloralintide in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Trial registry

PhasePhase 3

Population800 participants

DurationApproximately 76 weeks

Design and population

Two randomized, double-blind, placebo-controlled studies within one obstructive-sleep-apnea program

Adults with moderate-to-severe obstructive sleep apnea and obesity or overweight, with separate PAP-use contexts

Outcomes measured

Apnea-hypopnea index
Percent change in body weight
Sleep and functional measures
Safety and tolerability

What was reported

ENLIGHTEN-3 was recruiting with no results posted as of the July 30, 2026 evidence cutoff.

Study administration and important limits

Study administration: Once-weekly subcutaneous eloralintide or placebo

Limitations: No outcome can be inferred from an active registration. Weight change alone would also not establish a direct sleep-apnea effect without the prespecified trial results.

Community

Experience reports stay separate from published evidence

Loading Community Intelligence…

Built by the community

Help strengthen the Eloralintide experience record

Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.

Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.

Sources

Trace every major statement

Trial registry

ENLIGHTEN-1: A Study of Eloralintide in Participants With Obesity, or Overweight Without Type 2 Diabetes

2026-07-17 · NCT07321886

Trial registry

Trial registry

ENLIGHTEN-2: A Study of Eloralintide in Participants With Obesity or Overweight, and Type 2 Diabetes

2026-06-23 · NCT07282600

Trial registry

Trial registry

ENLIGHTEN-4: Efficacy and Safety of Eloralintide in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

2026-06-23 · NCT07353931

Trial registry

Trial registry

ENLIGHTEN-6: A Study of Eloralintide in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

2026-06-23 · NCT07392190

Trial registry

Trial registry

ENLIGHTEN-3: A Study of Eloralintide in Participants With Obstructive Sleep Apnea and Obesity or Overweight

2026-06-04 · NCT07369011

Trial registry

Peer reviewed

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

2026-01-20 · PMID 41559929 · NCT05295940 · DOI 10.1111/dom.70439

Peer reviewed

Peer reviewed

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

2025-11-06 · PMID 41207310 · NCT06230523 · DOI 10.1016/S0140-6736(25)02155-5

Peer reviewed

Peer reviewed

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

2025-10-16 · PMID 41109426 · NCT05295940 · DOI 10.1016/j.molmet.2025.102271

Peer reviewed

Loading the next view…

Eloralintide

Eloralintide at a glance

Why people research it

What the evidence supports

Eloralintide is an investigational selective amylin receptor agonist in Phase 3 development, not an FDA-approved medicine.

Eloralintide was designed to activate human AMY1R more selectively than calcitonin and AMY3 receptors.

A 48-week randomized Phase 2 trial found dose-related average body-weight reduction with eloralintide in adults without type 2 diabetes.

Early Phase 1 studies established once-weekly pharmacokinetic feasibility and produced short-term weight-loss signals.

Nausea and fatigue were the most common adverse events in the Phase 2 trial, with rates that varied across dose and escalation arms.

The ENLIGHTEN program is testing eloralintide across obesity without diabetes, obesity with type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and persistent obesity during incretin therapy.

Published and registered eloralintide studies describe once-weekly subcutaneous administration, but they do not provide consumer dosing guidance.

No public, regulator-approved eloralintide reconstitution, storage, or stability instructions were identified.

Eloralintide should not be treated as interchangeable with cagrilintide, incretin medicines, or combination regimens.

What needs caution

Dosing & preparation

Eloralintide · Phase 2 dose groups

Preparation & concentration · SubQ

Eloralintide Phase 2 study material

How it works

Signals and targets

Proposed biological steps

How mature is the evidence?

Which product or study does this describe?

Study-by-study record

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Design and population

Outcomes measured

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Design and population

Outcomes measured

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

Design and population

Outcomes measured

ENLIGHTEN-1: A Study of Eloralintide in Participants With Obesity, or Overweight Without Type 2 Diabetes

Design and population

Outcomes measured

ENLIGHTEN-2: A Study of Eloralintide in Participants With Obesity or Overweight, and Type 2 Diabetes

Design and population

Outcomes measured

ENLIGHTEN-4: Efficacy and Safety of Eloralintide in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Design and population

Outcomes measured

ENLIGHTEN-6: A Study of Eloralintide in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Design and population

Outcomes measured

ENLIGHTEN-3: A Study of Eloralintide in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Design and population

Outcomes measured

Experience reports stay separate from published evidence

Help strengthen the Eloralintide experience record

Keep the question moving

Trace every major statement

ENLIGHTEN-1: A Study of Eloralintide in Participants With Obesity, or Overweight Without Type 2 Diabetes

ENLIGHTEN-2: A Study of Eloralintide in Participants With Obesity or Overweight, and Type 2 Diabetes

ENLIGHTEN-4: Efficacy and Safety of Eloralintide in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

ENLIGHTEN-6: A Study of Eloralintide in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

ENLIGHTEN-3: A Study of Eloralintide in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept